MEK抑制剂治疗NF1相关高级别胶质瘤:单中心队列与文献综述
该单中心回顾性研究纳入9例NF1相关高级别胶质瘤成人患者,评估司美替尼、米达美替尼或达拉非尼联合曲美替尼的疗效。3例米达美替尼治疗中2例可评估患者达部分缓解,其余可评估患者最佳疗效为疾病稳定;中位无进展生存期2.9个月,中位总生存期9.4个月。
要点
- 米达美替尼在部分NF1相关HGG患者中观察到影像学部分缓解。
- 司美替尼及达拉非尼联合曲美替尼可评估患者最佳疗效为疾病稳定。
- MEKi起始后中位PFS为2.9个月,中位OS为9.4个月,获益持久性有限。
核心结论
- 米达美替尼治疗NF1相关HGG可观察到影像学部分缓解,但获益持久性有限。
- 司美替尼和达拉非尼联合曲美替尼在可评估患者中最佳疗效为疾病稳定。
- 需更大规模前瞻性研究明确MEK抑制在该人群中的作用。
研究设计与样本
- 共纳入9例患者,接受司美替尼、米达美替尼或达拉非尼联合曲美替尼治疗。
- 结局包括影像学反应及从MEKi启动时起的PFS和OS的Kaplan-Meier估计。
主要发现
- HGG发病中位年龄34岁(范围22-58),MEKi启动时中位Karnofsky体能状态评分60(范围50-90)。
- 诊断包括伴毛样特征的高级别星形细胞瘤(n=6)、IDH野生型胶质母细胞瘤(n=2)和IDH野生型HGG非特指(n=1)。
- 3例米达美替尼治疗患者中2例可评估患者按RANO标准达部分缓解。
- 6例接受司美替尼1-7个周期,1例接受达拉非尼/曲美替尼2个周期,其余可评估患者最佳疗效为疾病稳定。
- MEKi启动后中位PFS为2.9个月,中位OS为9.4个月。
关键数值与推荐
- 部分缓解依据Response Assessment in Neuro-Oncology(RANO)标准判定。
- 进展定义为最早记录的影像学或临床进展证据。
临床怎么用
- 对于NF1相关HGG成人患者,MEKi(尤其米达美替尼)可考虑作为个体化治疗选择,但需告知获益持久性可能有限。
- 治疗期间应密切进行影像学和临床评估以监测进展。
局限性
- 回顾性单中心设计,样本量小(9例),结论外推受限。
- 各MEKi亚组例数少,无法进行组间比较。
- 米达美替尼组仅2例可评估反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NF1-associated high-grade gliomas (HGGs) are rare, biologically heterogeneous tumors with poor outcomes. Although MEK inhibitors (MEKis) are established options for selected NF1-associated low-grade gliomas, their role in NF1-associated HGG remains undefined. We describe clinical and radiographic outcomes with MEKis, including mirdametinib. METHODS: We retrospectively reviewed adult patients with NF1-associated HGG treated at The University of Texas MD Anderson Cancer Center who initiated selumetinib, mirdametinib, or dabrafenib plus trametinib from December 1, 2019, to January 31, 2026. Outcomes included radiographic response and Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) from MEKi initiation. Progression was defined as the earliest documented radiographic or clinical evidence of progression. RESULTS: Nine patients were included. Median age at HGG onset was 34 years (range, 22-58), and median Karnofsky Performance Status at MEKi initiation was 60 (range, 50-90). Diagnoses were high-grade astrocytoma with piloid features (n = 6), IDH-wildtype glioblastoma (n = 2), and IDH-wildtype HGG/not otherwise specified (n = 1). Most patients received MEKi after prior local and/or systemic therapy. Among three patients treated with mirdametinib, two evaluable patients achieved partial response by Response Assessment in Neuro-Oncology criteria. Six patients received selumetinib for 1-7 cycles, and one patient received dabrafenib/trametinib for 2 cycles. Stable disease was the best response among the remaining evaluable patients. Median PFS and OS from MEKi initiation were 2.9 and 9.4 months, respectively. CONCLUSION: Radiographic partial responses were observed in two patients with NF1-associated HGG treated with mirdametinib, but durability of benefit was limited. The best response with selumetinib and dabrafenib/trametinib was stable disease in evaluable patients. Larger prospective studies are needed to define the role of MEK inhibition in this population.
引用
- Yu MC, Hsi AH, Adnan A, et al. MEK inhibitors in NF1-associated high-grade glioma: partial responses and outcomes from a single-institution cohort and literature review. J Neurooncol. 2026. PMID: 42918957. doi:10.1007/s11060-026-05835-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。